210 related articles for article (PubMed ID: 19952729)
1. Good response to second-line bevacizumab and interferon-alpha in a sunitinib-refractory patient with metastatic renal cell carcinoma.
Pastorelli D; Zustovich F; Faggioni G; Zovato S; Donach M; Nicoletto O; Farina M; Furini L; Ceravolo R; Carli P; Lombardi G
Anticancer Drugs; 2010 Feb; 21(2):210-3. PubMed ID: 19952729
[TBL] [Abstract][Full Text] [Related]
2. Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series.
Medioni J; Banu E; Helley D; Scotte F; Fournier L; Mejean A; Chedid A; Azizi M; Andrieu JM; Oudard S
Eur Urol; 2009 Jul; 56(1):207-11; quiz 211. PubMed ID: 19157688
[TBL] [Abstract][Full Text] [Related]
3. Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy.
Schmidinger M; Zielinski CC
Cancer Treat Rev; 2009 May; 35(3):289-96. PubMed ID: 19232474
[TBL] [Abstract][Full Text] [Related]
4. Tolerability of first-line therapy for metastatic renal cell carcinoma.
Porta C; Szczylik C
Cancer Treat Rev; 2009 May; 35(3):297-307. PubMed ID: 19249157
[TBL] [Abstract][Full Text] [Related]
5. Update on systemic therapies of metastatic renal cell carcinoma.
Herrmann E; Bierer S; Wülfing C
World J Urol; 2010 Jun; 28(3):303-9. PubMed ID: 20180125
[TBL] [Abstract][Full Text] [Related]
6. [First-line therapy of metastatic renal cell carcinoma--update 2009].
Miller K
Onkologie; 2010; 33 Suppl 1():5-9. PubMed ID: 20164669
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of the management of metastatic renal cell carcinoma in the era of targeted therapies. retrospective clinical study over six years].
Latteux G; Lebdai S; Hoarau N; Abadie-Lacourtoisie S; Delva R; Chautard D; Azzouzi AR; Bigot P
Prog Urol; 2013 Mar; 23(3):184-94. PubMed ID: 23446283
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of serum CA9 in patients with metastatic clear cell renal cell carcinoma under targeted therapy.
Gigante M; Li G; Ferlay C; Perol D; Blanc E; Paul S; Zhao A; Tostain J; Escudier B; Negrier S; Genin C
Anticancer Res; 2012 Dec; 32(12):5447-51. PubMed ID: 23225450
[TBL] [Abstract][Full Text] [Related]
9. Comment on 'costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib'.
Charbonneau C; Sandin R
Br J Cancer; 2010 Oct; 103(8):1307-8; author reply 1309-10. PubMed ID: 20938457
[No Abstract] [Full Text] [Related]
10. Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma.
Cella D
Oncologist; 2011; 16 Suppl 2(Suppl 2):23-31. PubMed ID: 21346037
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness.
Thompson Coon JS; Liu Z; Hoyle M; Rogers G; Green C; Moxham T; Welch K; Stein K
Br J Cancer; 2009 Jul; 101(2):238-43. PubMed ID: 19568242
[TBL] [Abstract][Full Text] [Related]
12. Toxicity of sunitinib plus bevacizumab in renal cell carcinoma.
Rini BI; Garcia JA; Cooney MM; Elson P; Tyler A; Beatty K; Bokar J; Ivy P; Chen HX; Dowlati A; Dreicer R
J Clin Oncol; 2010 Jun; 28(17):e284-5; author reply e286-7. PubMed ID: 20439632
[No Abstract] [Full Text] [Related]
13. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies.
Hutson TE; Figlin RA; Kuhn JG; Motzer RJ
Oncologist; 2008 Oct; 13(10):1084-96. PubMed ID: 18838439
[TBL] [Abstract][Full Text] [Related]
14. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Miller K; Bergmann L; Albers P; Gschwend J; Jäger E; Keilholz U
Aktuelle Urol; 2010 May; 41(3):193-6. PubMed ID: 20486036
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab plus interferon-α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis.
Ravasio R; Ortega C; Sabbatini R; Porta C
Clin Drug Investig; 2011; 31(7):507-17. PubMed ID: 21627339
[TBL] [Abstract][Full Text] [Related]
16. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.
Mickisch G; Gore M; Escudier B; Procopio G; Walzer S; Nuijten M
Br J Cancer; 2010 Jan; 102(1):80-6. PubMed ID: 19920817
[TBL] [Abstract][Full Text] [Related]
17. [Value of targeted therapies for renal cell cancer].
Merseburger AS; Kuczyk MA
Urologe A; 2008 Oct; 47(10):1303-10. PubMed ID: 18587556
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials.
Iacovelli R; Alesini D; Palazzo A; Trenta P; Santoni M; De Marchis L; Cascinu S; Naso G; Cortesi E
Cancer Treat Rev; 2014 Mar; 40(2):271-5. PubMed ID: 24070900
[TBL] [Abstract][Full Text] [Related]
19. Regarding: 'Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib'.
Porta C
Br J Cancer; 2010 Mar; 102(7):1196-7. PubMed ID: 20179707
[No Abstract] [Full Text] [Related]
20. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Golshayan AR; George S; Heng DY; Elson P; Wood LS; Mekhail TM; Garcia JA; Aydin H; Zhou M; Bukowski RM; Rini BI
J Clin Oncol; 2009 Jan; 27(2):235-41. PubMed ID: 19064974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]